Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients

References

• Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306–318. doi:10.1093/schbul/sbr148
   PubMed Web of Science ®Google Scholar
• Baller JB, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence. BMC Psychiatry. 2015;15:55. doi:10.1186/s12888-015-0416-y
   PubMed Web of Science ®Google Scholar
• Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–781. doi:10.1007/s40264-017-0543-0
   PubMed Web of Science ®Google Scholar
• Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res. 2007;4(1):32–38. doi:10.3132/dvdr.2007.003
   PubMedGoogle Scholar
• Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm Metab Res. 2007;39(9):642–650. doi:10.1055/s-2007-985822
   Web of Science ®Google Scholar
• Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73. doi:10.31887/DCNS.2018.20.1/bpenninx
   PubMed Web of Science ®Google Scholar
• Howell S, Yarovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart. 2019;105(24):1852–1859. doi:10.1136/heartjnl-2017-312107
   PubMed Web of Science ®Google Scholar
• Micucci C, Valli D, Matacchione G, Catalano A. Current perspectives between metabolic syndrome and cancer. Oncotarget. 2016;7(25):38959–38972. doi:10.18632/oncotarget.8341
   Google Scholar
• Bellastella G, Scappaticcio L, Esposito K, Giugliano D, Maiorino MI. Metabolic syndrome and cancer: “The common soil hypothesis. Diabetes Res Clin Pract. 2018;143:389–397. doi:10.1016/j.diabres.2018.05.024
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61(8):1356–1370. doi:10.1111/j.1742-1241.2007.01416.x
   PubMed Web of Science ®Google Scholar
• Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010;123(2–3):244–250. doi:10.1016/j.schres.2010.08.030
   PubMed Web of Science ®Google Scholar
• Lee J, Nurjono M, Wong A, Salim A. Prevalence of metabolic syndrome among patients with schizophrenia in Singapore. Ann Acad Med Singap. 2012;41(10):457–462.
   Web of Science ®Google Scholar
• Tian Y, Liu D, Wang D, et al. Obesity in Chinese patients with chronic schizophrenia: prevalence, clinical correlates and relationship with cognitive deficits. Schizophr Res. 2020;215:270–276. doi:10.1016/j.schres.2019.10.017
   PubMed Web of Science ®Google Scholar
• Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One. 2016;11(11):e0166429. doi:10.1371/journal.pone.0166429
   PubMed Web of Science ®Google Scholar
• van der Hoeven F, Schimmang T, Volkmann A, Mattei MG, Kyewski B, Rüther U. Programmed cell death is affected in the novel mouse mutant Fused toes (Ft). Development. 1994;120(9):2601–2607. doi:10.1242/dev.120.9.2601
   Web of Science ®Google Scholar
• Peters T, Ausmeier K, Rüther U. Cloning of Fatso (Fto), a novel gene deleted by the Fused toes (Ft) mouse mutation. Mamm Genome. 1999;10(10):983–986. doi:10.1007/s003359901144
   PubMed Web of Science ®Google Scholar
• Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894. doi:10.1126/science.1141634
   PubMed Web of Science ®Google Scholar
• Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3(7):e115. doi:10.1371/journal.pgen.0030115
   PubMed Web of Science ®Google Scholar
• Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev. 2008;9(3):246–250. doi:10.1111/j.1467-789X.2008.00481.x
   PubMed Web of Science ®Google Scholar
• Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. Trends Genet. 2010;26(6):266–274. doi:10.1016/j.tig.2010.02.006
   PubMed Web of Science ®Google Scholar
• Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469–1472. doi:10.1126/science.1151710
   PubMed Web of Science ®Google Scholar
• Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–887. doi:10.1038/nchembio.687
   PubMed Web of Science ®Google Scholar
• Fischer J, Koch L, Emmerling C, et al. Inactivation of the Fto gene protects from obesity. Nature. 2009;458(7240):894–898. doi:10.1038/nature07848
   PubMed Web of Science ®Google Scholar
• Gao X, Shin YH, Li M, Wang F, Tong Q, Zhang P. The fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One. 2010;5(11):e14005. doi:10.1371/journal.pone.0014005
   PubMed Web of Science ®Google Scholar
• Church C, Moir L, McMurray F, et al. Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet. 2010;42(12):1086–1092. doi:10.1038/ng.713
   PubMed Web of Science ®Google Scholar
• Zhou Y, Kong Y, Fan W, et al. Principles of RNA methylation and their implications for biology and medicine. Biomed Pharmacother. 2020;131:110731. doi:10.1016/j.biopha.2020.110731
   PubMed Web of Science ®Google Scholar
• He PC, He C. m6 A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40(3):e105977. doi:10.15252/embj.2020105977
   Web of Science ®Google Scholar
• Ganeff IMM, Bos MM, van Heemst D, Noordam R. BMI-associated gene variants in FTO and cardiometabolic and brain disease: obesity or pleiotropy? Physiol Genomics. 2019;51(8):311–322. doi:10.1152/physiolgenomics.00040.2019
   Web of Science ®Google Scholar
• Annapoorna PK, Iyer H, Parnaik T, Narasimhan H, Bhattacharya A, Kumar A. FTO: an emerging molecular player in neuropsychiatric diseases. Neuroscience. 2019;418:15–24. doi:10.1016/j.neuroscience.2019.08.021
   Web of Science ®Google Scholar
• Lan N, Lu Y, Zhang Y, et al. FTO - a common genetic basis for obesity and cancer. Front Genet. 2020;11:559138. doi:10.3389/fgene.2020.559138
   PubMed Web of Science ®Google Scholar
• Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–726. doi:10.1038/ng2048
   PubMed Web of Science ®Google Scholar
• Herman MA, Rosen ED. Making biological sense of GWAS data: lessons from the FTO locus. Cell Metab. 2015;22(4):538–539. doi:10.1016/j.cmet.2015.09.018
   Web of Science ®Google Scholar
• Smemo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507(7492):371–375. doi:10.1038/nature13138
   PubMed Web of Science ®Google Scholar
• Claussnitzer M, Dankel SN, Kim KH, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373(10):895–907. doi:10.1056/NEJMoa1502214
   PubMed Web of Science ®Google Scholar
• Tóth BB, Arianti R, Shaw A, et al. FTO intronic SNP strongly influences human neck adipocyte browning determined by Tissue and PPARγ specific regulation: a transcriptome analysis. Cells. 2020;9(4):987. doi:10.3390/cells9040987
   Web of Science ®Google Scholar
• Bjune JI, Dyer L, Røsland GV, et al. The homeobox factor Irx3 maintains adipogenic identity. Metabolism. 2020;103:154014. doi:10.1016/j.metabol.2019.154014
   Web of Science ®Google Scholar
• Villalobos-Comparán M, Teresa Flores-Dorantes M, Teresa Villarreal-Molina M, et al. The FTO gene is associated with adulthood obesity in the Mexican population. Obesity (Silver Spring). 2008;16(10):2296–2301. doi:10.1038/oby.2008.367
   PubMed Web of Science ®Google Scholar
• Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes. 2008;57(1):95–101. doi:10.2337/db07-0910
   PubMed Web of Science ®Google Scholar
• Ran S, Jiang ZX, He X, et al. Replication of FTO gene associated with lean mass in a meta-analysis of Genome-Wide Association Studies. Sci Rep. 2020;10(1):5057. doi:10.1038/s41598-020-61406-3
   Web of Science ®Google Scholar
• Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206. doi:10.1038/nature14177
   PubMed Web of Science ®Google Scholar
• Rampersaud E, Mitchell BD, Pollin TI, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med. 2008;168(16):1791–1797. doi:10.1001/archinte.168.16.1791
   PubMedGoogle Scholar
• Rodríguez-López R, González-Carpio M, Serrano MV, et al. Asociación de polimorfismos en el gen FTO con la obesidad mórbida en la población extremeña [Association of FTO gene polymorphisms and morbid obesity in the population of Extremadura (Spain)]. Endocrinol Nutr. 2010;57(5):203–209. doi:10.1016/j.endonu.2010.03.002
   PubMedGoogle Scholar
• Tönjes A, Zeggini E, Kovacs P, et al. Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur J Hum Genet. 2010;18(1):104–110. doi:10.1038/ejhg.2009.107
   Web of Science ®Google Scholar
• Tan LJ, Zhu H, He H, et al. Replication of 6 obesity genes in a meta-analysis of genome-wide association studies from diverse ancestries. PLoS One. 2014;9(5):e96149. doi:10.1371/journal.pone.0096149
   Web of Science ®Google Scholar
• Khan SM, El Hajj Chehadeh S, Abdulrahman M, Osman W, Al Safar H. Establishing a genetic link between FTO and VDR gene polymorphisms and obesity in the Emirati population. BMC Med Genet. 2018;19(1):11. doi:10.1186/s12881-018-0522-z
   Web of Science ®Google Scholar
• Al Asoom LI, Al Afandi DT, Al Abdulhadi AS, Rafique N, Chathoth S, Al Sunni AA. Protective association of single nucleotide polymorphisms rs1861868-FTO and rs7975232-VDR and obesity in Saudi females. Int J Gen Med. 2020;13:235–241. doi:10.2147/IJGM.S251466
   PubMed Web of Science ®Google Scholar
• Reynolds GP. Pharmacogenetic aspects of antipsychotic drug-induced weight gain - a critical review. Clin Psychopharmacol Neurosci. 2012;10(2):71–77. doi:10.9758/cpn.2012.10.2.71
   Google Scholar
• Kao AC, Muller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics. 2013;14(16):2067–2083. doi:10.2217/pgs.13.207
   PubMed Web of Science ®Google Scholar
• Malan-Müller S, Kilian S, van den Heuvel LL, et al. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophr Res. 2016;170(1):1–17. doi:10.1016/j.schres.2015.11.011
   PubMed Web of Science ®Google Scholar
• Luo C, Liu J, Wang X, Mao X, Zhou H, Liu Z. Pharmacogenetic correlates of antipsychotic-induced weight gain in the Chinese population. Neurosci Bull. 2019;35(3):561–580. doi:10.1007/s12264-018-0323-6
   Web of Science ®Google Scholar
• Corfitsen HT, Krantz B, Larsen A, Drago A. Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain. Acta Neuropsychiatr. 2020;32(2):72–83. doi:10.1017/neu.2019.41
   Web of Science ®Google Scholar
• Roffeei SN, Mohamed Z, Reynolds GP, et al. Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics. 2014;15(4):477–485. doi:10.2217/pgs.13.220
   Web of Science ®Google Scholar
• Kornetova EG, Kornetov AN, Mednova IA, et al. Comparative characteristics of the metabolic syndrome prevalence in patients with schizophrenia in three western Siberia psychiatric hospitals. Front Psychiatry. 2021;12:661174. doi:10.3389/fpsyt.2021.661174
   Web of Science ®Google Scholar
• Paderina DZ, Boiko AS, Pozhidaev IV, et al. Genetic polymorphisms of 5-HT receptors and antipsychotic-induced metabolic dysfunction in patients with schizophrenia. J Pers Med. 2021;11(3):181. doi:10.3390/jpm11030181
   Web of Science ®Google Scholar
• World Health Organization. International Statistical Classification of Diseases and Health Related Problems ICD-10. Geneva, VH: World Health Organization; 2004.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255–262. doi:10.1016/j.biopsych.2009.08.040
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–480. doi:10.1111/j.1464-5491.2006.01858.x
   PubMed Web of Science ®Google Scholar
• Lewontin RC. The interaction of selection and linkage. I. general considerations; heterotic models. Genetics. 1964;49(1):49–67. doi:10.1093/genetics/49.1.49
   PubMed Web of Science ®Google Scholar
• Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr. 2011;14(10):1702–1713. doi:10.1017/S1368980010003320
   Web of Science ®Google Scholar
• Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res. 2017;120:34–42. doi:10.1016/j.phrs.2017.03.008
   PubMed Web of Science ®Google Scholar
• Schröder C, Czerwensky F, Leucht S, Steimer W. Fat mass and obesity-related gene variants rs9939609 and rs7185735 are associated with second-generation antipsychotic-induced weight gain. Pharmacopsychiatry. 2019;52(1):16–23. doi:10.1055/s-0043-125392
   Web of Science ®Google Scholar
• Huang MC, Kao CF, Chiu CC, et al. The genetic association of FTO variants with metabolic traits in patients with schizophrenia may be modified by antipsychotics. J Clin Psychopharmacol. 2014;34(1):162–165. doi:10.1097/JCP.0b013e3182a95b20
   Web of Science ®Google Scholar
• Gassó P, Arnaiz JA, Mas S, et al. Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. J Psychopharmacol. 2020;34(5):514–523. doi:10.1177/0269881120903462
   Web of Science ®Google Scholar
• Wang F, Mi W-F, Lu T-L, Ruan -Y-Y, Zhang D, Yue W-H. Association study of FTO gene polymorphism with weight gain associated with 4 week risperidone treatment. Chin Ment Health J. 2013;27(2):157–160.
   Google Scholar
• Song X, Pang L, Feng Y, et al. Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. Behav Brain Funct. 2014;10(1):35. doi:10.1186/1744-9081-10-35
   Web of Science ®Google Scholar
• Díaz-Anzaldúa A, Ocampo-Mendoza Y, Hernández-Lagunas JO, et al. Differences in body mass index according to fat mass- and obesity-associated (FTO) genotype in Mexican patients with bipolar disorder. Bipolar Disord. 2015;17(6):662–669. doi:10.1111/bdi.12328
   Web of Science ®Google Scholar
• Reynolds GP, Yevtushenko OO, Gordon S, Arranz B, San L, Cooper SJ. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. Int J Neuropsychopharmacol. 2013;16(6):1421–1425. doi:10.1017/S1461145712001435
   PubMed Web of Science ®Google Scholar
• Nurmi EL, Spilman SL, Whelan F, et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry. 2013;3(6):e274. doi:10.1038/tp.2013.26
   Web of Science ®Google Scholar
• Shing EC, Tiwari AK, Brandl EJ, et al. Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. Neuropsychobiology. 2014;69(1):59–63. doi:10.1159/000356231
   PubMed Web of Science ®Google Scholar
• Jassim G, Fernø J, Theisen FM, et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry. 2011;44(1):15–20. doi:10.1055/s-0030-1263174
   Web of Science ®Google Scholar
• Watanabe SY, Iga J, Numata S, et al. Association study of fat-mass and obesity-associated gene and body mass index in Japanese patients with schizophrenia and healthy subjects. Clin Psychopharmacol Neurosci. 2012;10(3):185–189. doi:10.9758/cpn.2012.10.3.185
   Google Scholar
• de Silva VA, Muneeswaran K, Ratnatunga SS, et al. Genetic association between antipsychotic induced weight gain and FTO gene in a Sri Lankan population. Ceylon Med J. 2019;64(2):40–45. doi:10.4038/cmj.v64i2.8889
   Web of Science ®Google Scholar